FDA OKs Clinical Trial to Test Bacteriophage-Based Treatment for Crohn’s

FDA OKs Clinical Trial to Test Bacteriophage-Based Treatment for Crohn’s
The U.S. Food and Drug Administration (FDA) recently cleared a Phase 1/2a clinical trial to study a set of bacteriophages designed to treat inflammatory bowel diseases (IBDs), specifically Crohn’s disease. The bacteriophages were developed as part of a July 2015 collaboration agreement between Intralytix and Ferring Pharmaceuticals. Together with French researchers from the University of Lille

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *